Personalizing cancer Immunotherapy with our DNA
Takis NeoMatrix EIT HealthCatapult HD

NEOMATRIX is a individualised therapeutic cancer vaccine against tumour specific antigens, called neoantigens, arising from somatic gene mutations in malignant cells during neoplastic transformation. The tailored vaccine is intended for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours.

The process

  • Tumor Biopsies are taken from patient
  • RNA and DNA are sequenced by Next Generation Sequences
  • Neoantigens are identified through a pipeline called NARciso
  • Codon Optimized Vaccine is synthesized in Takis Laboratories
  • 100-150mg DNA plasmids are manufactured in GMP conditions
  • The entire process is predicted to be back to the patient in 6 weeks

The process

To learn how NeoMatrix works click here

To learn how NeoMatrix works click here

Where we are

Preclinical studies completed

Biomarker assay under advanced development

Specialty Oncology Centers / KOLs identified and ready to start

Cancer Targets


Lung Cancer

Brands and Partners

We Closely Cooperate With Selected Brands to Ensure High Quality Equipment

Aurisicchio L, Pallocca M, Ciliberto G, Palombo F.
J Exp Clin Cancer Res. 2018 Apr 20;37(1):86. doi: 10.1186/s13046-018-0751-1

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874958


Luigi Aurisicchio, CEO
Neomatrix biotech - Rome, Italy

Fabio Palombo, CSO
Neomatrix biotech - Rome, Italy